Vurolenatide is a recombinant peptide commercialized by 9 Meters Biopharma, with a leading Phase III program in Short Bowel Syndrome. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vurolenatide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vurolenatide is expected to reach an annual total of $160 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NB-1001 (XTEN-GLP1) is under development for the treatment of short bowl syndrome. NB-1001 is a proprietary long-acting version of exenatide. NB-1001 is administered through subcutaneous route as a replacement therapy. The drug candidate acts by targeting GLP-1 receptor. The drug candidate is developed based on the XTEN platform technology. NB-1001 was also under development for type II diabetes.
9 Meters Biopharma Overview
9 Meters Biopharma, formerly Innovate Biopharmaceuticals Inc, is a clinical-stage biopharmaceutical company developing novel medicines for autoimmune and inflammatory diseases. The company’s pipeline products include Larazotide, an orally administered, gut-restricted tight-junction regulator for celiac disease, NM-003, a long-acting GLP-2 analog, under orphan indication selection, NM-136 and NM-004. 9 Meters Biopharma is headquartered in Raleigh, North Carolina, the US.
The operating loss of the company was US$42 million in FY2022, compared to an operating loss of US$36.8 million in FY2021. The net loss of the company was US$43.8 million in FY2022, compared to a net loss of US$36.8 million in FY2021.
For a complete picture of Vurolenatide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.